TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: QTc effect (ΔΔQTcF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: change in HbA1c from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in weight from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: readmission rate for any cause at 1 month
Endpoint domain: Mortality/survival
Primary endpoint: Chemotherapy treatment failure due to HFS
Endpoint domain: Adverse events/effects
Primary endpoint: Survival rate at 5 and 8 years
Endpoint domain: Mortality/survival
Primary endpoint: Physical activity motivation
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Adolescent adherence to Fitbit usage
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: sudden cardiovascular death
Endpoint domain: Mortality/survival
Primary endpoint: Biliary cannulation success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk for suicide within 5 years after lung cancer diagnosis
Endpoint domain: Mortality/survival
Primary endpoint: Reduced mortality rates one year after surgery
Endpoint domain: Mortality/survival
Primary endpoint: NRS ≥5 at rest
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 30% reduction in ODI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Revision for infection
Endpoint domain: Adverse events/effects
Primary endpoint: Revision for mechanical failure
Endpoint domain: Adverse events/effects
Primary endpoint: Increase in knowledge score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Reduction in hair fall
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Surface area of precipitation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ca content of surface deposits
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ca/P ratio of surface deposits
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improving functional outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: transfer to response inhibition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Bone-forming activity measured by standardized uptake values (SUV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Post-ERCP Pancreatitis (PEP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: neuropsychological functioning
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Flameng score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: SQS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Corneal epitheliopathy incidence
Endpoint domain: Adverse events/effects
Primary endpoint: proportion of cases of RCSI
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: probability of RCSI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Erectile dysfunction (IIEF-5 ≥17)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sufficient erection for intercourse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incontinence recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Empathy development
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Swallowing quality of life
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: coefficient variation of blood glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Variability of accommodation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Supplemental oxygen amount
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Response rate after radioactive iodine therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CAS (Clinical Activity Score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Delta proptosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FRpeak parameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Barognosis results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Roughness differentiation results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total tramadol consumption
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: days of severe neutropenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: FMA-UE score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MAS grades of elbow joint and metacarpophalangeal joint
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Proportion of older adults participating in faecal immunohistochemical testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite death or moderate to severe disability at 2 years
Endpoint domain: Mortality/survival
Primary endpoint: Improvement in delayed memory performance
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: VAD prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Jadad score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Van Tulder score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decisional conflict about prostate cancer screening
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Knowledge improvement about prostate cancer screening
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: 6-month cohort PCS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Mean reduction in CRP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mental health outcomes (frequent mental distress)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: High-risk behaviors for human immunodeficiency virus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Uninsured status
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: vasospasm-related morbidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: poor clinical outcome (GOSE score ≥ 4)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: exercise motivation scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Composite cardiorenal outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Prevalence of symptoms of anxiety
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of symptoms of depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of symptoms of PTSD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: REEDA score on the 10th day postpartum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Difference in the proportion of contaminated patients
Endpoint domain: Adverse events/effects
Primary endpoint: Skills of evaluation, induction, and inference
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Eyebrow skin thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dermal fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anxiety visual analogue scale (AVAS) scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Total number of postoperative analgesic pumps
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Successful guide-wire insertion on the first attempt
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Time to successful guide-wire insertion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Fasting and 2-hour post-prandial blood glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pro-inflammatory cytokines (C-reactive protein, TNF-α, interleukin-6)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Midterm quality of life
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: mild-to-severe anxiety symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: mild-to-severe depression symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: suicidal behavior
Endpoint domain: Adverse events/effects
Primary endpoint: Postoperative IOP drop
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete success rates (IOP≤21 mm Hg without ocular hypotensive medications)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Qualified success rates (IOP≤21 mm Hg with or without ocular hypotensive medications)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum cortisol:cortisone ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: high blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Stillbirth or neonatal death
Endpoint domain: Mortality/survival
Primary endpoint: Glucocorticoid-free remission at week 16
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative glucocorticoid dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Critical Cultural Competence Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall performance
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Diarrhoea morbidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: death from all causes through 180 days
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of allogeneic transfusion
Endpoint domain: Adverse events/effects
Primary endpoint: Skin roughness of stretch marks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Skin firmness of stretch marks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Dermal density and thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: mean decrease in maximum keratometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidences of grade 4 myelosuppression
Endpoint domain: Adverse events/effects
Primary endpoint: Mean Eurocran dental index scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of hope
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Total SGRQ score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Impact dimension score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Symptoms dimension score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Renal Perfusion (RPF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Renal Vascular Resistance (RVR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: EMGFI delta value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in nose and lip aesthetics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in total Agatston score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Development of COVID-19 infection
Endpoint domain: Mortality/survival
Primary endpoint: cost-effectiveness per QALYs gained
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: HPV clearance rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lesion complete remission (CR) rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neurosensory function recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Packer composite clinical endpoint
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Neonatal morbidity rate
Endpoint domain: Mortality/survival
Primary endpoint: ICU admission rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: time until sufficient sedation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: performer satisfaction level
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Low-risk alcohol consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduced risk of late-onset sepsis
Endpoint domain: Adverse events/effects
Primary endpoint: Change in TMD pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 2-step or greater improvement in DRSS level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of vision-threatening complications and/or center-involved DME
Endpoint domain: Adverse events/effects
Primary endpoint: 90-day modified Rankin Scale score of 0 to 2
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Weight-loss outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resolution rates of obesity-related comorbidities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of Depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: ANC4+ coverage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improve clinical outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximize independence
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Reduction in total gabapentinoid prescriptions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Initiations to psychologists
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion of ACTs sold to malaria test-positive clients
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Seroconversion rates (RVNA titres ≥ 0.5 IU/mL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: RVNA geometric mean titres (GMTs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Health-related quality of life (HRQoL) at 1 year
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: serious neonatal morbidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Incidence of exudative AMD (eAMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean time to eAMD diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of patients with disability worsening confirmed at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total amount of analgesic used
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severe toxicities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: YBT scoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: remission of hypertension
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: %EBMIL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in physical and/or sexual IPV
Endpoint domain: Adverse events/effects
Primary endpoint: absolute change in lung clearance index2.5
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: professional help-seeking intentions for mental health problems
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Peak root mean square in PM (peak RMS-PM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Rate of force development (RFD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Frequency of acute COPD exacerbations
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: persistent organ dysfunction syndrome plus death at day 28
Endpoint domain: Mortality/survival
Primary endpoint: days alive and free of vasopressors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: good treatment outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: biochemically validated tobacco abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in severity of pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total 24 hour consumption of Morphine
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Positive response rate to TT vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Positive response rate to ≥5 serotypes in 23-PPV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Seroprotection rates against 5 influenza strains
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Median time for intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GHQ score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Carotid Β‐Stiffness Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: persistent gluteal or posterior thigh pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EEG resting state theta
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: anxiety and mood disturbance
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Postintervention plaque scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase of FI scores of shoulder flexion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: decrease in symptom count
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for transfusion of red blood cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Median NRS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total consumption of postoperative rescue analgesic diclofenac
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: mean BRA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: score of 'good' or 'excellent' by panel assessment at 5 years
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: body image questionnaire top score at 5 years
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Child's sleep quality
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Prediction of NRF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: epoetin dosage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: macroscopic complete CRS‐HIPEC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clavien‐Dindo grade 3 or higher postoperative morbidity
Endpoint domain: Adverse events/effects
Primary endpoint: objective radiologic response rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Kansas City Cardiomyopathy Questionnaire score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Improvement reported on the PGI-I
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage improvement of collagen content
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage improvement of elastin content
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mVSS improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: inferior survival
Endpoint domain: Mortality/survival
Primary endpoint: Bioequivalence of terazosin formulations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Failure rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes